Skip to main content
Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Ultrasensitive bioassaying of HER-2 protein for diagnosis of breast cancer using reduced graphene oxide/chitosan as nanobiocompatible platform

Fig. 6

Identification of the HER-2 in untreated serum samples from breast cancer patients. a The ECL plots; b the correlated histograms. The error bares were obtained by three ECL measurements for each sample and c immunohistochemical imaging of breast samples in cancer patients. The HER-2 positive cells were indicated by the black arrows (brown-colored cells)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us